437 related articles for article (PubMed ID: 30036854)
1. Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
Cascione M; Tenenbaum N; Wendt J; Meng X; Schofield L; Cree BAC;
Mult Scler Relat Disord; 2018 Oct; 25():50-56. PubMed ID: 30036854
[TBL] [Abstract][Full Text] [Related]
2. Phase IV study of retention on fingolimod
Cree BAC; Arnold DL; Cascione M; Fox EJ; Williams IM; Meng X; Schofield L; Tenenbaum N
Ther Adv Neurol Disord; 2018; 11():1756286418774338. PubMed ID: 29844796
[TBL] [Abstract][Full Text] [Related]
3. Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes
Hunter SF; Thomas FP; Cascione M; Williams IM; Meng X; Schofield L; Weiss JL; Tenenbaum N; Cree BAC;
Mult Scler Relat Disord; 2020 Oct; 45():102346. PubMed ID: 32717684
[TBL] [Abstract][Full Text] [Related]
4. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE).
Tuncer MA; Kürtüncü M; Terzi M; Uygunoğlu U; Göncüoğlu C; Yüceyar AN; Ekmekçi Ö; Türkoğlu R; Soysal A; Köseoğlu M; Boz C; Beckmann Y; Turan ÖF; Demirkıran DM; Akman FG; Altunrende B; Cantürk İA; Birday E; Özcan A; Kamişli Ö; Özen NPA; Çelik RGG; Balcı FB; Efendi H; Sarıkaya C; Akçalı A; Toprak MK; Kabay SC; Kızılay F; Sevim MS; Gazaloğlu GB; Demir CF; Balgetir F; Kıylıoğlu N; Sarıahmetoğlu H; Ölmez Ç; Mavi K; Yüksel S; Işık N; Saip S; Karabudak R; Siva A; Eraksoy M
Turk J Med Sci; 2023 Feb; 53(1):323-332. PubMed ID: 36945929
[TBL] [Abstract][Full Text] [Related]
6. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.
Hunter SF; Agius M; Miller DM; Cutter G; Barbato L; McCague K; Meng X; Agashivala N; Chin P; Hollander E
J Neurol Sci; 2016 Jun; 365():190-8. PubMed ID: 27206905
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
Braune S; Lang M; Bergmann A;
J Neurol; 2016 Feb; 263(2):327-333. PubMed ID: 26645389
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod for relapsing-remitting multiple sclerosis.
La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
[TBL] [Abstract][Full Text] [Related]
10. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
English C; Aloi JJ
Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
[TBL] [Abstract][Full Text] [Related]
11. Newer disease modifying treatments in pediatric onset multiple sclerosis: Experience from a single center.
Solmaz I; Acar Ozen P; Parlak S; Tuncer A; Anlar B
Eur J Paediatr Neurol; 2022 Jul; 39():110-115. PubMed ID: 35777190
[TBL] [Abstract][Full Text] [Related]
12. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
13. Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate.
Williams MJ; Johnson K; Trenz HM; Korrer S; Halpern R; Park Y; Herrera V
Curr Med Res Opin; 2018 Jan; 34(1):107-115. PubMed ID: 28857632
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Fox E; Edwards K; Burch G; Wynn DR; LaGanke C; Crayton H; Hunter SF; Huffman C; Kim E; Pestreich L; McCague K; Barbato L;
Mult Scler Relat Disord; 2014 Sep; 3(5):607-19. PubMed ID: 26265273
[TBL] [Abstract][Full Text] [Related]
15. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Johnston J; So TY
Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Kubala Havrdova E; Patti F; Shaygannejad V; Ozakbas S; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Duquette P; Terzi M; Boz C; Grand'Maison F; Sola P; Ferraro D; Grammond P; Yamout B; Altintas A; Gerlach O; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Hughes S; Sa MJ; Solaro C; Kappos L; Hodgkinson S; Slee M; Granella F; de Gans K; McCombe PA; Ampapa R; van der Walt A; Butzkueven H; Sánchez-Menoyo JL; Vucic S; Laureys G; Sidhom Y; Gouider R; Castillo-Trivino T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Al-Harbi TM; Csepany T; Sempere AP; Treviño Frenk I; Stuart EA; Kalincik T
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1004-1011. PubMed ID: 37414534
[TBL] [Abstract][Full Text] [Related]
17. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Li H; Hu F; Zhang Y; Li K
J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
[TBL] [Abstract][Full Text] [Related]
19. Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.
Derfuss T; Ontaneda D; Nicholas J; Meng X; Hawker K
Mult Scler Relat Disord; 2016 Jul; 8():124-30. PubMed ID: 27456887
[TBL] [Abstract][Full Text] [Related]
20. Neurometabolic changes in multiple sclerosis: Fingolimod versus beta interferon or glatiramer acetate therapy.
Al-Iedani O; Lea R; Ribbons K; Ramadan S; Lechner-Scott J
J Neuroimaging; 2022 Nov; 32(6):1109-1120. PubMed ID: 35922880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
